Cross-protection is crucial for prophylactic HPV vaccination

The Lancet Infectious Diseases

Volumn 12, Issue 10, 2012, Pages 742-743

  Lehtinen, Matti ^a  

^a TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

ANTIBODY RESPONSE; CONDYLOMA ACUMINATUM; FOLLOW UP; HELPER CELL; HUMAN; LETTER; MEMORY CELL; PRIORITY JOURNAL; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION;

CROSS PROTECTION; HUMANS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84866623625     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(12)70203-7     Document Type: Letter

References (9)

1. Malagón T, Drolet M, Boily M-C, et al. Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis. Lancet Infect Dis 2012, published online Aug 22. http://dx.doi.org/10.1016/S1473-3099(12)70187-1.
2. Namujju PB, Banura C, Mbidde EK, et al. Low avidity of human papillomavirus type 16 (HPV16) antibodies is associated with increased susceptibility to low-risk but not high-risk HPV infections. BMC Res Notes 2011, 6:170.
3. Dauner JG, Pan Y, Hildesheim A, Harro C, Pinto LA Characterization of the HPV-specific memory B cell and systemic antibody responses in women receiving an unadjuvanted HPV16 L1 VLP vaccine. Vaccine 2010, 28:5407-5413.
4. Rizk RZ, Christensen ND, Michael KM, et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008, 89:117-129.
5. Bishop B, Dasgupta J, Klein M, et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007, 282:31803-31811.
6. Lehtinen M, Paavonen J Sound efficacy of prophylactic HPV vaccination. Basics and implications. Oncoimmunology 2012, 1:1-2.
7. Lehtinen M, Herrero R, Mayaud P, et al. Studies to assess long-term efficacy and effectiveness of HPV vaccination in developed and developing countries. Vaccine 2006, 24:233-241.
8. Einstein MH, Baron M, Levin MJ, et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthywomen aged 18-45 years. Hum Vaccin 2011, 7:1359-1373.
9. Weinberger DM, Malley R, Lipsitch M Serotype replacement in disease after pneumococcal vaccination. Lancet 2011, 378:1962-1973.